Viamet Pharmaceuticals, which has received FDA “orphan drug” status for its fungus fighter, has landed a Department of Defense grant worth $1.95 million to fight mold infections in wounds.
The grant also means new research into topical treatments for the company.
The funding comes through the Department of Defense Defense Medical Research and Development Program.
Money will be used to develop what Viamet calls “a novel topical antifungal agent to prevent and treat mold infections as a result of battlefield wounds.”
The grant is for three years.
“We believe that Viamet has the broadest and most robust portfolio of novel antifungal agents in the industry today,” said Viamet CEO Robert Schotzinger. “We look forward to extending the application of our novel compounds to include the prevention and treatment of mold infections resulting from battlefield wounds that occur in our US military personnel.”
Previous Viamet research has focused on antifungal agents delivered orally or intravenously.
“However, certain compounds are also appropriate for topical administration, including the potential to prevent and treat mold infections of battlefield wounds,” the company said.
Viamet planned to go public last year but withdrew a $75 million IPO in October and instead raised $60 million in new capital.
